News_News_Grand Life Sciences (Liaoning) Co., Ltd.,FDF,API& Intermediate

2025 10-27

Marketing Authorization Approval for the Flurbiprofen Active Pharmaceutical Ingredient (API)

We officially received the Marketing Authorization Approval for the Flurbiprofen Active Pharmaceutical Ingredient (API) from the National Medical Products Administration (NMPA).

MORE

2025 10-27

Grand Life Sciences (Liaoning) Shines at CPHI Shanghai 2025: Innovation Drives the Future of Medicine

CPHI Shanghai 2025 was successfully held at Shanghai New International Expo Center from June 24 to 26, 2025.

MORE

2024 07-12

Grand Life Sciences (Liaoning) Shines at CPHI & PMEC China 2024

On June 21, 2024, the 22nd CPHI China and the 17th PMEC China successfully concluded at the Shanghai New International Expo Centre

MORE

2024 07-12

Yuanda Shuyang's New Production Base for Blood Products Officially Put into Operation

On April 8, 2022, a new production base (West High-tech Zone) for blood products of Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd.("Yuanda Shuyang"), a wholly-owned subsidiary of Yuanda Life Science Group Co., Ltd, was officially put into operation, marking the comprehensive upgrade of Yuanda Shuyang's informatized and industrialized manufacturing platform for blood products. This also promoted the company's high-quality development in implementing the Made in China 2025 and Healthy China 2030 strategies.

MORE